- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00911430
Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection
December 14, 2019 updated by: National Institute of Allergy and Infectious Diseases (NIAID)
The incidence of community-associated (CA) staphylococcal infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA), has increased dramatically in recent years.
Although the majority of these infections are limited to the skin and soft tissue and thus not life threatening, the number of invasive cases in otherwise healthy individuals is increasing and some are fatal.
As a first step toward understanding pathogenesis, there has been significant focus on elucidating the key CA-MRSA virulence factors.
The relative significance of these factors is still being delineated.
By comparison, there has been little focus on host factors associated with these invasive infections.
In this protocol, we will recruit 100 otherwise healthy subjects with invasive staphylococcal infection, 50 otherwise healthy subjects with recurrent staphylococcal infections, and obtain samples from 150 unidentified healthy controls from the blood bank to investigate host immunologic factors predisposing people to staphylococcal infection.
Subjects will receive standard of care treatment for acute or recurrent staphylococcal infections.
The primary objective of this research is to identify host genetic factors that contribute to susceptibility or severity of community acquired staphylococcal diseases.
We will use three experimental approaches to complete this objective: 1) expression microarray analyses of study population s (subjects and controls) white cells (neutrophils and peripheral blood mononuclear cells) at rest and stimulated with staphylococci, 2) evaluation of toll-like receptor (TLR) pathways in the study population s cells, and 3) evaluation of Th17 cells.
The proposed research will address a key area of staphylococcal pathogenesis for which there is a striking lack of information.
We fully anticipate that the research also will provide critical new information directly relevant to vaccine, diagnostics, and therapeutics development.
Study Overview
Status
Terminated
Detailed Description
The incidence of community-associated (CA) staphylococcal infections, especially those caused by methicillin-resistant Staphylococcus aureus (MRSA), has increased dramatically in recent years.
Although the majority of these infections are limited to the skin and soft tissue and thus not life threatening, the number of invasive cases in otherwise healthy individuals is increasing and some are fatal.
As a first step toward understanding pathogenesis, there has been significant focus on elucidating the key CA-MRSA virulence factors.
The relative significance of these factors is still being delineated.
By comparison, there has been little focus on host factors associated with these invasive infections.
In this protocol, we will recruit 100 otherwise healthy subjects with invasive staphylococcal infection, 50 otherwise healthy subjects with recurrent staphylococcal infections, and obtain samples from 150 unidentified healthy controls from the blood bank to investigate host immunologic factors predisposing people to staphylococcal infection.
Subjects will receive standard of care treatment for acute or recurrent staphylococcal infections.
The primary objective of this research is to identify host genetic factors that contribute to susceptibility or severity of community acquired staphylococcal diseases.
We will use three experimental approaches to complete this objective: 1) expression microarray analyses of study population s (subjects and controls) white cells (neutrophils and peripheral blood mononuclear cells) at rest and stimulated with staphylococci, 2) evaluation of toll-like receptor (TLR) pathways in the study population s cells, and 3) evaluation of Th17 cells.
The proposed research will address a key area of staphylococcal pathogenesis for which there is a striking lack of information.
We fully anticipate that the research also will provide critical new information directly relevant to vaccine, diagnostics, and therapeutics development.
Study Type
Observational
Enrollment (Actual)
22
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years and older (ADULT, OLDER_ADULT, CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
INCLUSION CRITERIA:
- Age greater than or equal to 2 years.
- Current or past S. aureus infection, either invasive or soft tissue.
- Willingness to allow storage of blood and tissue samples for future use.
- Subjects will be eligible without regard to race, gender, or ethnic origin.
EXCLUSION CRITERIA:
- Infection with known HIV-1, HIV-2 as demonstrated by ELISA and Western blot or viral load testing.
- Evidence of intravenous drug abuse in the year prior to the first (or only) S. aureus infection.
- Previously known immunodeficiency syndrome.
- Evidence of active malignancy.
- Any condition that the investigators judge would compromise the results of the study.
- Diabetes mellitus.
- Evidence of healthcare-associated infection invasive device, history of surgery with implantation of artificial device in previous 12 months, history of surgery without device implantation in previous 12 month, or dialysis, hospitalization, or residence in long-term care facility in previous 12 months. An exception to these exclusion criteria is hospitalization for the acute S. aureus infection at the time of enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Naimi TS, LeDell KH, Como-Sabetti K, Borchardt SM, Boxrud DJ, Etienne J, Johnson SK, Vandenesch F, Fridkin S, O'Boyle C, Danila RN, Lynfield R. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA. 2003 Dec 10;290(22):2976-84. doi: 10.1001/jama.290.22.2976.
- Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M; SENTRY Partcipants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001 May 15;32 Suppl 2:S114-32. doi: 10.1086/320184.
- Zetola N, Francis JS, Nuermberger EL, Bishai WR. Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis. 2005 May;5(5):275-86. doi: 10.1016/S1473-3099(05)70112-2.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 28, 2009
Study Completion
September 17, 2014
Study Registration Dates
First Submitted
May 29, 2009
First Submitted That Met QC Criteria
May 29, 2009
First Posted (Estimate)
June 2, 2009
Study Record Updates
Last Update Posted (Actual)
December 17, 2019
Last Update Submitted That Met QC Criteria
December 14, 2019
Last Verified
September 17, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 090157
- 09-I-0157
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Staphylococcal Aureus Infection
-
University of PennsylvaniaChildren's Hospital of Philadelphia; Milton S. Hershey Medical Center; Pennsylvania...CompletedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Massachusetts General HospitalTerminatedMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
CAMC Health SystemUnknownMRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States
-
Erasme University HospitalCompletedStaphylococcus Aureus | Staphylococcal Infection | Methicillin ResistanceBelgium
-
B. Braun Medical SATerminatedMRSA - Methicillin Resistant Staphylococcus Aureus Infection | MRSA ColonizationSpain
-
Menzies School of Health ResearchThe University of Queensland; Australasian Society for Infectious Diseases; Singapore... and other collaboratorsTerminatedMethicillin-Resistant Staphylococcus AureusAustralia, New Zealand, Israel, Singapore
-
R. Stephen Rankin, M.D.UnknownCommunity-acquired Methicillin-resistant Staphylococcus Aureus InfectionUnited States
-
Inova Health Care ServicesCardinal HealthTerminatedMethicillin-resistant Staphylococcus Aureus InfectionUnited States
-
Washington University School of MedicineActive, not recruitingStaphylococcus Aureus | Skin and Subcutaneous Tissue Bacterial Infections | MRSA - Methicillin Resistant Staphylococcus Aureus InfectionUnited States